Dr Charles R Gordon Joins Wenzel Spine as Executive Chairman

Wenzel Spine, Inc., a medical technology company focused on providing minimally invasive surgical and diagnostic solutions for the treatment of spinal disorders, today is pleased to announce the expansion of its executive leadership team by appointing Dr Charles R Gordon as the Executive Chairman of the Board. This strategic move is poised to enhance the company’s innovative edge and entry into the minimally invasive interventional spine market.

William Wilson, CEO of Wenzel Spine, commented on the recent expansion, saying, “The addition of Dr. Gordon to our executive team and our engagement with MM Dillon & Co. represent significant steps forward for Wenzel Spine. We are confident that these strategic moves will enhance our ability to deliver innovative and effective spine solutions addressing our entry into MI interventional spine for our clients, partners and their patients.”

Dr. Gordon was the founding Chairman of the Board for Baylor Scott & White’s Texas Spine & Joint Hospital. Over the years the hospital has grown, and majority interest of the hospital was sold to Baylor Scott & White and United Surgical Partners International (USPI). The real estate was also sold in a separate transaction to a large publicly traded real estate investment trust. Dr. Gordon holds over 80 distinct patents all in the life science area. He remains active in medical practice and is excited about the possibility of adding value to his partners and stakeholders, across-the-board. “I am thrilled to join the Wenzel Spine executive leadership team,” said Dr. Gordon. “I believe my extensive experience and proven track record in the industry will be invaluable as we continue to grow and innovate in the field of spine care. I think Wenzel Spine has the capability to quickly enter the minimally invasive interventional spine market with unique technologies.”

In addition to expanding its leadership team, Wenzel Spine has engaged with MM Dillon & Co., a boutique investment bank, to assist with strategic options, which may include raising capital for strategic growth. Michiel McCarty, Chairman & CEO of MM Dillon & Co., expressed his enthusiasm about the engagement, stating, “We are excited to work with Wenzel Spine, a company that is at the forefront of innovation in spine care. Our team is committed to assisting Wenzel Spine in exploring strategic options to further their growth and impact in the industry.”

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”